The knowledge of ATMPs in Italy is quite limited (e.g only one gene therapy has been reimbursed yet), but it is expected to grow in the very next future, becoming an important challenge for Italian NHS. Italy currently has a competitive advantage compared to other Countries, in terms of expertise, but there is a need to start Stakeholders discussion on this innovation coming.
Create an ongoing platform, involving all stakeholders, toward the common objective of making Italy a leading Country in the ATMP field.
Under the auspices of:
Con il supporto di: